← Leaderboards
Mallikarjun Srivatsan
Accurius Therapeutics, Inc.
$1,399,999
Attributed
$1,399,999
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1M · FY2023–24$1M$750K$500K$250K$0
'23
'24
Funding mix
By agency
NIH$1,399,999 · 1
By mechanism
R44$1,399,999 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Animal Model”
- Mari Ostendorf · University Of Washington$51,931,230
- Dorota A. Grejner-Brzezinska · University Of Wisconsin-Madison$19,883,568
- Kevin Saunders · Duke University$18,106,404
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
- Heinz Ernst Moser · University Of Texas Med Br Galveston$12,973,432
- Maximilian Haeussler · University Of California Santa Cruz$12,592,563
Research focus
Animal ModelAnimalsAnti-Tumor Immune ResponseBody Weight DecreasedBreathingCancer CellCancer ModelCancer PatientCell Culture TechniquesCellsCessation Of LifeChemotherapyClinicClinical ResearchCollaborationsCombination Drug TherapyCommercial ApplicationCommercializationDiagnosticDisseminated Malignant NeoplasmDistantDoseDrug TargetingAgreement
Grant awards (2)
Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)$1,000,000
R44 · FY2024 · CA · contact PI
Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV)$399,999
R44 · FY2023 · CA · contact PI